Supernus Pharmaceuticals
SUPN
297 hedge funds and large institutions have $1.98B invested in Supernus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 100 increasing their positions, 108 reducing their positions, and 28 closing their positions.
82% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 28
8% more funds holding
Funds holding: 275 → 297 (+22)
3% less capital invested
Capital invested by funds: $2.03B → $1.98B (-$51.8M)
7% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 108
3.34% less ownership
Funds ownership: 100.27% → 96.94% (-3.3%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
46% less call options, than puts
Call options by funds: $2.73M | Put options by funds: $5.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$9.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$7.33M |
| 3 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$7.25M |
| 4 |
JP Morgan Chase
New York
|
+$6.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$18.9M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$17.5M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$12.7M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$9.71M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$8.21M |
SUPN Hedge Fund Activity: Q4 2017 in Review
297 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2017, worth a combined $1.98B — down 2.5% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new SUPN positions and 28 closed out — a net gain of 23 holders — while 100 added to existing stakes and 108 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $9.5M. The largest seller was Invesco, cutting an estimated $18.9M.
- 297 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2017, up from 275 in Q3 2017.
- Funds reported $1.98B of Supernus Pharmaceuticals stock for Q4 2017, down 2.5% quarter-over-quarter.
- 51 funds opened new Supernus Pharmaceuticals positions in Q4 2017 and 28 closed out, a net change of +23 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2017 was Bellevue Group, an estimated $9.5M added.
- The largest Supernus Pharmaceuticals seller in Q4 2017 was Invesco, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2017.